The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50 - 1/100.
1/100 - 1/500. Detects a band of approximately 71 kDa (predicted molecular weight: 71 kDa).
FunctionCatalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle.
Involvement in diseaseDefects in PCK2 are the cause of mitochondrial phosphoenolpyruvate carboxykinase deficiency (M-PEPCKD) [MIM:261650]. A metabolic disorder resulting from impaired gluconeogenesis. It is a rare disease with less than 10 cases reported in the literature. Clinical characteristics include hypotonia, hepatomegaly, failure to thrive, lactic acidosis and hypoglycemia. Autoposy reveals fatty infiltration of both the liver and kidneys. The disorder is transmitted as an autosomal recessive trait.
Sequence similaritiesBelongs to the phosphoenolpyruvate carboxykinase [GTP] family.
Post-translational modificationsPhosphorylated upon DNA damage, probably by ATM or ATR.
ab71745 at 1/50 dilution, staining PCK2 in human breast carcinoma by Immunohistochemistry, Formalin-fixed, Paraffin-embedded tissue, followed by peroxidase-conjugated secondary antibody and AEC staining.
References for Anti-PCK2 antibody - C-terminal (ab71745)
has not yet been referenced specifically in any publications.
Publishing research using ab71745? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"